Search results for: Health Policy and Regulation
Filter search results
A Spotlight on Haemophilia Therapies
3 October 2024
…bodies must foster a supportive policy environment that recognises and rewards innovation, including intellectual property protection, transparent approval requirements and processes, and pricing and reimbursement policies that incentivise and reward…
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
…threshold in three years’ time and establishes a valuable precedent. Cost-effectiveness thresholds should evolve with changing health system constraints and not remain static as has been the case with the…
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
…two separate health technology assessment (HTA) processes: one for medicines, and one for other health technologies (such as medical devices). Assessment of other health technologies RedETS is the acronym for…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
…patients, healthcare providers). A reconciling effort OHE’s approach reconciles the economic and health service literature, developing a framework and indicators of valued output for primary care in England. To this…
Alan Maynard – Alas No More
5 February 2018
…of Alan Maynard, the pioneering health economist, and why they… Tony Culyer writes on the contribution to health economics of Alan Maynard, the pioneering health economist, who died on February…
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…Germany, Ireland, Italy, Poland, Scotland and Spain. Via a series of literature reviews and discussions with an expert panel, we find four main ways in which the results of BIA…
Reimagining Prevention for a Healthier, More Prosperous Society
12 October 2023
…cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary measures, can help to reduce ill health, improve healthcare capacity, and increase wider economic growth….
The CBO Doesn’t Understand Investors
13 September 2021
…have adverse consequences for population health—both in the US and globally. In the face of rapid scientific progress, such as we have seen with the development of COVID-19 vaccines and…
Trade and Price Differentials for Pharmaceuticals: Policy Options
1 May 1997
…presence of joint costs. Section 4 identifies the winners and losers from parallel trade. Sections 5 and 6 discuss policy options to minimize the adverse impact of parallel trade and…